{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:03:49Z","timestamp":1782662629416,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Comparable indicators on complete cancer prevalence are increasingly needed in Europe to support survivorship care planning. Direct measures can be biased by limited registration time and estimates are needed to recover long term survivors. The completeness index method, based on incidence and survival modelling, is the standard most validated approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Within this framework, we consider two alternative approaches that do not require any direct modelling activity: i) empirical indices derived from long established European registries; ii) pre-calculated indices derived from US-SEER cancer registries. Relying on the EUROCARE-6 study dataset we compare standard vs alternative complete prevalence estimates using data from 62 registries in 27 countries by sex, cancer type and registration time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For tumours mostly diagnosed in the elderly the empirical estimates differ little from standard estimates (on average less than 5% after 10-15 years of registration), especially for low prognosis cancers. For early-onset cancers (bone, brain, cervix uteri, testis, Hodgkin disease, soft tissues) the empirical method may produce substantial underestimations of complete prevalence (up to 20%) even when based on 35-year observations. SEER estimates are comparable to the standard ones for most cancers, including many early-onset tumours, even when derived from short time series (10-15 years). Longer observations are however needed when cancer-specific incidence and prognosis differ remarkably between US and European populations (endometrium, thyroid or stomach).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results may facilitate the dissemination of complete prevalence estimates across Europe and help bridge the current information gaps.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1114701","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:07:27Z","timestamp":1682503647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes"],"prefix":"10.3389","volume":"13","author":[{"given":"Elena","family":"Demuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Dal Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Guzzinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Katalinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Jooste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EUROCARE-6 Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<425::AID-SIM414>3.0.CO;2-Z","article-title":"Estimating the completeness of prevalence based on cancer registry data","volume":"16","author":"Capocaccia","year":"1997","journal-title":"Stat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ije\/29.2.197","article-title":"Cancer prevalence estimates based on tumour registry data in the surveillance, epidemiology, and end results (SEER) program","volume":"29","author":"Merrill","year":"2000","journal-title":"Int J Epidemiol"},{"key":"B3","volume-title":"SEER cancer statistics review, 1975-2017, National Cancer Institute","author":"Howlader","year":"2020"},{"key":"B4","unstructured":"Surveillance research program. national cancer institute COMPREV software"},{"key":"B5","unstructured":"Global cancer observatory"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray","year":"2013","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.08.001","article-title":"Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project","volume":"37","author":"Mallone","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"B9","unstructured":"Rarecare-net project, work package on rare cancers epidemiology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf127","volume":"13","author":"Micheli","year":"2002","journal-title":"Cancer prevalence European registry areas. Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf152","article-title":"Mugno e on behalf of the EUROPREVAL working group. Measuring cancer prevalence in Europe: the EUROPREVAL project","volume":"13","author":"Capocaccia","year":"2002","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12885-018-4053-y","article-title":"Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020","volume":"18","author":"Guzzinati","year":"2018","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19191\/EP14.6.S1.113","article-title":"Italian Cancer figures, report 2014: Prevalence and cure of cancer in Italy","volume":"38","year":"2014","journal-title":"Epidemiol Prev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-52","article-title":"German Cancer statistics 2004","volume":"10","author":"Haberland","year":"2010","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canep.2018.08.001","article-title":"Time trends and short term projections of cancer prevalence in France","volume":"56","author":"Colonna","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12885-015-1168-2","article-title":"Total and partial cancer prevalence in the adult French population in 2008","volume":"15","author":"Colonna","year":"2015","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.366","article-title":"Projections of cancer prevalence in the united kingdom, 2010-2040","volume":"107","author":"Maddams","year":"2012","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1700\/1334.14807","article-title":"Estimates of cancer burden in Italy","volume":"99","author":"Rossi","year":"2013","journal-title":"Tumori"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-287","article-title":"Cancer survivors in Switzerland: a rapidly growing population to care for","volume":"13","author":"Herrmann","year":"2013","journal-title":"BMC Cancer"},{"key":"B20","unstructured":"NORDCAN online data tool, version 9.2"},{"key":"B21","unstructured":"Slovenian cancer registry annual reports."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the united states: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12913-020-05265-8","article-title":"The economic burden of prostate cancer - a Swedish prevalence-based register study","volume":"20","author":"Hao","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-767","article-title":"The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care","volume":"14","author":"Sharp","year":"2014","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \"Silver tsunami\": Prevalence trajectories and comorbidity burden among older cancer survivors in the united states","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S380390","article-title":"Cancer cure and consequences on survivorship care: Position paper from the Italian alliance against cancer (ACC) survivorship care working group","volume":"14","author":"Dal Maso","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34413","article-title":"Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites","volume":"128","author":"Colonna","year":"2022","journal-title":"Cancer"},{"key":"B28","unstructured":"iPAAC joint action, work package 7 on cancer information and registries"},{"key":"B29","unstructured":"European Network of cancer registries (ENCR) call for data protocol 201"},{"key":"B30","volume-title":"Surveillance research program, national cancer institute SEER*Stat software version 8.3.9.2.","year":""},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countrie","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-96","article-title":"Estimating and modelling cure in population-based cancer studies within the frame-work of flexible parametric survival models","volume":"11","author":"Andersson","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANEP.2013.08.014","article-title":"Estimating the proportion cured of cancer: Some practical advice for users","volume":"37","author":"Yu","year":"2013","journal-title":"Cancer Epidemiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1114701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:07:36Z","timestamp":1682503656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1114701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":33,"alternative-id":["10.3389\/fonc.2023.1114701"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1114701","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"article-number":"1114701"}}